You just read:

OncoGenex Announces Top-Line Survival Results of Phase 3 SYNERGY Trial Evaluating Custirsen for Metastatic Castrate-Resistant Prostate Cancer

News provided by

OncoGenex Pharmaceuticals, Inc.

Apr 28, 2014, 07:10 ET